These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 5935707)

  • 41. Forces required for surgical dilatation of the pregnant and non-pregnant human cervix.
    Anthony GS; Fisher J; Coutts JR; Calder AA
    Br J Obstet Gynaecol; 1982 Nov; 89(11):913-6. PubMed ID: 7171498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy.
    Mauck CK; Callahan MM; Baker J; Arbogast K; Veazey R; Stock R; Pan Z; Morrison CS; Chen-Mok M; Archer DF; Gabelnick HL
    Contraception; 1999 Jul; 60(1):15-24. PubMed ID: 10549448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Depo-Provera use in an Australian metropolitan practice.
    Fraser IS; Dennerstein GJ
    Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.
    Gemzell-Danielsson K; Swahn ML; Svalander P; Bygdeman M
    Hum Reprod; 1993 Jun; 8(6):870-3. PubMed ID: 8345076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Depo-provera: clinical evaluation.
    Mukherjea M
    Contracept Deliv Syst; 1981 Jul; 2(3):259-69. PubMed ID: 12278913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of visible disruption of cervical epithelium and cervical ectopy in African women using Depo-Provera.
    Kuhn L; Denny L; Pollack AE; Wright TC
    Contraception; 1999 Jun; 59(6):363-7. PubMed ID: 10518230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
    Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
    Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.
    Swahn ML; Johannisson E; Daniore V; de la Torre B; Bygdeman M
    Hum Reprod; 1988 Oct; 3(7):915-21. PubMed ID: 2846630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The ultrastructural response of human endometrium to medroxyprogesterone acetate.
    Roberts DK; Horbelt DV; Powell LC
    Am J Obstet Gynecol; 1975 Dec; 123(8):811-8. PubMed ID: 173189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of the combined steroidal contraceptives (Gynanovlar 21 and Lyndiol 2.5) on the human adrenocortical and ovarian activities.
    Zaki K; Kamal I; Talaat MM; Rashad S; Nour H
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):41-65. PubMed ID: 12256027
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Danazol has progestin-like actions on the human endometrium.
    Kokko E; Jänne O; Kauppila A; Rönnberg L; Vihko R
    Acta Endocrinol (Copenh); 1982 Apr; 99(4):588-93. PubMed ID: 6461996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term contraception with Depo-Provera: a clinical evaluation.
    Mukherjea M; Mukherjee P; Biswas R
    Int J Fertil; 1980; 25(2):122-6. PubMed ID: 6117526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ovarian function during lactation.
    Badraoui MH; Hefnawi F
    Popul Sci; 1982; (2):95-107. PubMed ID: 12339786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: noresthisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects.
    Contraception; 1978 May; 17(5):395-406. PubMed ID: 657807
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endometrial vasculature in Norplant users.
    Rogers PA
    Hum Reprod; 1996 Oct; 11 Suppl 2():45-50. PubMed ID: 8982745
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Depo-Provera highly effective as injectable contraceptive.
    Denniston GC
    Contracept Technol Update; 1985 Dec; 6(12):167-8. PubMed ID: 12280301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.